Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286810 | 0.98 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A | |
| SCHEMBL18883054 | 0.98 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A | |
| SCHEMBL225938 | 0.98 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A | |
| SCHEMBL22560813 | 0.83 | ACHE (0.42) | MAOBHTR1A | |
| SCHEMBL21982512 | 0.78 | MAP3K14 (0.43) | NISCHSIGMAR1HTR1AOXTRCHRM2 | |
| SCHEMBL21557506 | 0.78 | MAP3K14 (0.43) | NISCHSIGMAR1HTR1AOXTRCHRM2 | |
| SCHEMBL15127606 | 0.78 | ABCG2 (0.50) | NISCH | |
| SCHEMBL25082548 | 0.73 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A | |
| SCHEMBL7587627 | 0.73 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A | |
| SCHEMBL14395682 | 0.73 | NISCH (0.45) | NISCHSIGMAR1MAOBTP53HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | NISCH 1087/4885SIGMAR1 1196/4885MAOB 2360/4885 |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR5, CCR1 | NISCH 3043/4885SIGMAR1 1932/4885MAOB 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.